BioPharma Drive: Drug Pricing

DECEMBER 13, 2023

The company is now expecting to save $4 billion by the end of 2024, with a majority of the spending cuts coming from drug research and development.

Drug Research 293

Drug Research Research Drugs 293

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

Vial

MAY 20, 2024

In this article, we will define preclinical and clinical CROs, as well as highlight the unique needs and challenges of these organizations in their respective stages of drug research. between 2024 and 2030. between 2024 and 2030. What is a Pre-Clinical CRO? billion in 2022 and is projected to reach US$10.2

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

ACTO

SEPTEMBER 11, 2024

The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster to patients waiting in need,” said Parth Khanna, CEO of ACTO. Current solutions are almost exclusively focused on marketing, HCP targeting, workflow automation, and performance insight.

Science 52

Science Pharma Companies Production Marketing 52

Agency IQ

JUNE 7, 2024

BY LAURA DIANGELO, MPH | JUN 5, 2024 5:35 PM CDT Background: The FDA’s Bioresearch Monitoring (BIMO) program In FDA’s words, the BIMO program is “a comprehensive program of on-site inspections, data audits, and remote regulatory assessments designed to monitor all aspects of the conduct and reporting of FDA regulated research.”

FDA 40

FDA Compliance Regulations Production 40

Agency IQ

AUGUST 2, 2024

What we expect European regulators to do in August and September 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.

Regulations 40

Regulations Clinical Trials Production Trials 40

Agency IQ

JUNE 9, 2023

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. Parliament will be elected in 2024, which could further slow down the process. Additionally, a new E.U.

Marketing 40

Marketing Regulations Biosimilars Drugs 40